INTRODUCTION {#S1}
============

The incidence of nonmelanoma and melanoma skin cancers has been increasing in the United States over recent decades ([@R28]; [@R29]; [@R34]). Epidemiological evidence suggests that there is a causal relationship between sun/UV exposure and the three major histologic forms of skin cancer: squamous cell carcinoma, basal cell carcinoma, and cutaneous melanoma ([@R10]; [@R15]; [@R35]). Individuals with fair skin and/or poor tanning ability are at higher risk for developing these malignancies ([@R1]), which are uncommon in darkly pigmented individuals ([@R26]). During UV-induced tanning, DNA damage in keratinocytes triggers p53-mediated transcription of the pro-opiomelanocortin (*POMC*) gene ([@R7]). Proteolytic cleavage of POMC produces alpha-MSH (melanocyte-stimulating hormone), which binds to the melanocortin-receptor-1 (MC1R) on melanocytes, activating adenylate cyclase. Elevated cyclic AMP (cAMP) activates protein kinase A (PKA), which phosphorylates the cAMP-responsive-element-binding protein (CREB) ([@R23]; [@R31]), which, in turn, stimulates the transcription of the microphthalmia-associated transcription factor (*MITF*) gene ([@R2]; [@R27]). *MC1R* non-signaling variants are associated with lighter skin tones and red hair and are linked to poor tanning responses ([@R32]). Previously, topical application of the cAMP agonist forskolin was shown to rescue the cAMP-MITF-eumelanin pathway in *Mc1r*-deficient mice ([@R8]). Subsequent studies identified the phosphodiesterase PDE4D3 as a key regulator of melanocytic cAMP homeostasis, and its suppression produced hyperpigmentation similar to forskolin treatment in red-haired mice ([@R16]). However, attempts to apply both of these small-molecule approaches to human skin have been unsuccessful, likely related to poor skin penetration of the active species.

Genetic data in mice have suggested the presence of a pathway in which CREB-regulated transcription co-activator (CRTC) positively regulates and salt-inducible kinase 2 (SIK2) negatively regulates MITF and pigment synthesis independently of CREB phosphorylation by PKA ([@R13]). In macrophages, the small-molecule SIK inhibitor HG 9-91-01 has been shown to regulate CREB-dependent gene transcription by suppressing phosphorylation of CRTC ([@R6]), thereby inhibiting cytoplasmic sequestration and permitting its nuclear translocation. We hypothesized that small-molecule SIK inhibitors could be generated and optimized as topical agents capable of inducing cutaneous pigmentation independently of UV irradiation in human skin.

RESULTS {#S2}
=======

Small-Molecule Inhibition of SIK Induces *MITF* Expression In Vitro {#S3}
-------------------------------------------------------------------

To test regulation of the pigmentation pathway by the previously published SIK inhibitor HG 9-91-01 (HG) ([@R6]) in vitro, we treated normal human melanocytes, UACC62 human melanoma cells, and UACC257 human melanoma cells. Dose-dependent increases in expression of *MITF* were observed in these cells in response to SIK inhibitor application ([Figures 1A](#F1){ref-type="fig"}, [S1A, and S1D](#SD1){ref-type="supplementary-material"}). RNA levels of the MITF target gene *TRPM1* ([@R22]) also increased and followed the anticipated delayed kinetics relative to *MITF* induction in normal human melanocytes ([Figures 1B and 1C](#F1){ref-type="fig"}) and UACC257 human melanoma cells ([Figures S1G and S1H](#SD1){ref-type="supplementary-material"}). Gross pigmentation was observed in cell pellets of UACC257 human melanoma cells after 3 days of HG 9-91-01 treatment ([Figure 1D](#F1){ref-type="fig"}). Since SIK kinase activity is known to be dependent on LKB1 ([@R14]) we next evaluated whether SIK-inhibitor treatment of LKB1-null G361 melanoma cells would induce MITF. In LKB1-null G361 melanoma cells, there is no *MITF* induction with SIK-inhibitor treatment ([Figure S1J](#SD1){ref-type="supplementary-material"}). In contrast, when LKB1 is introduced in G361 melanoma cells ([Figure S1I](#SD1){ref-type="supplementary-material"}), we observed a 6-fold induction of *MITF* expression with SIK-inhibitor treatment ([Figure S1K](#SD1){ref-type="supplementary-material"}), demonstrating the dependence of SIK-inhibitor effect on active SIK. These data suggest that small-molecule SIK inhibition can stimulate the pigmentation pathway in vitro.

HG 9-91-01 Rescues Melanogenesis in Mice with Inactive Melanocortin 1 Receptor {#S4}
------------------------------------------------------------------------------

Since our in vitro results demonstrated that inhibition of SIK by HG 9-91-01 positively regulated *MITF* transcription, we next evaluated whether topical application of this compound could induce pigmentation independent of MC1R in vivo. To test this, we utilized a previously described mouse "red hair" model that carries the inactivating *Mc1r^e/e^* mutant allele and a transgene, K14-SCF, in which stem cell factor expression is driven by the keratin-14 promoter, allowing for epidermal homing of melanocytes ([@R8]; [@R18]). Albino mice harboring a mutation in the *tyrosinase* gene were combined with the K14-SCF transgene (*Tyr^c/c^*;K14-SCF mice) and served as controls to evaluate whether the pigmentation afforded by topical SIK inhibitor was dependent upon the canonical tyrosinase-melanin pathway. Daily application of the SIK inhibitor HG 9-91-01 for 7 days caused robust darkening in *Mc1r^e/e^*;K14-SCF mice ([Figures 2A](#F2){ref-type="fig"} and [S2A](#SD1){ref-type="supplementary-material"}). No visible change in skin pigmentation was observed in *Mc1r^e/e^*;K14-SCF mice treated with vehicle or in *Tyr^c/c^*;K14-SCF mice treated with vehicle or HG 9-91-01 ([Figures 2A](#F2){ref-type="fig"}, [S2A, and S2B](#SD1){ref-type="supplementary-material"}). Reflective colorimetry analysis (Commission Internationale de l'Eclairage \[CIE\] L\* white-black color axis ([@R25])) revealed significant darkening in *Mc1r^e/e^*;K14-SCF mice treated with SIK inhibitor, but not in vehicle-treated *Mc1r^e/e^*;K14-SCF mice or in *Tyr*^c/c^;K14-SCF mice treated with either SIK inhibitor or vehicle control (70% ethanol, 30% propylene glycol) ([Figure 2B](#F2){ref-type="fig"}). Fontana-Masson staining, a specialized melanin stain, revealed strong induction of melanin production in *Mc1r^e/e^*;K14-SCF mice only in areas treated with HG 9-91-01 ([Figures 2C](#F2){ref-type="fig"} and [S2D](#SD1){ref-type="supplementary-material"}) but no pigment induction in *Mc1r^e/e^*;K14-SCF mice treated with vehicle ([Figure 2C](#F2){ref-type="fig"}) or in albino (*Tyr^c/c^*;K14-SCF) mice treated with either vehicle or SIK inhibitor ([Figure S2C](#SD1){ref-type="supplementary-material"}). Nuclear capping of melanin-laden melanosomes was observed within epidermal keratinocytes in *Mc1r^e/e^*;K14-SCF mice treated with HG 9-91-01 (indicated by white arrows) and represents a known subcellular localization typical of physiologic skin pigmentation ([@R17]) ([Figure 2C](#F2){ref-type="fig"}). This feature suggests that SIK-inhibitor treatment stimulates not only melanocytic pigment synthesis but also the export of melanin in a fashion that closely mimics the known pathway of UV melanogenesis. H&E staining revealed normal morphology of HG 9-91-01-treated *Mc1r^e/e^*;K14-SCF ([Figure 2C](#F2){ref-type="fig"}) and *Tyr^c/c^*;K14-SCF epidermis ([Figure S2C](#SD1){ref-type="supplementary-material"}). NaOH lysis of skin samples ([@R33]) revealed a visible increase in extractable eumelanin from *Mc1r^e/e^*;K14-SCF mice treated with HG 9-91-01, compared with all other treatment groups ([Figure 2D](#F2){ref-type="fig"}).

Darkening induced by topical application of HG 9-91-01 to *Mc1r^e/e^*;K14-SCF mice was progressive over 6 days of treatment and gradually reversed over the 2 weeks after treatment was stopped ([Figure 2F](#F2){ref-type="fig"}). Skin pigmentation remained in its pretreatment state 26 days later (40 days after treatment ended) ([Figure 2E](#F2){ref-type="fig"}). No change was observed in *Tyr*^c/c^;K14-SCF mice during treatment or 14 days after treatment was stopped ([Figure 2G](#F2){ref-type="fig"}). Forty days after treatment was stopped, Fontana-Masson staining of skin sections of *Mc1r^e/e^*;K14-SCF mice and Tyr^c/c^;K14-SCF mice revealed no differences between vehicle and treatment groups, and H&E staining illustrated normal morphology for all mice ([Figure S2E](#SD1){ref-type="supplementary-material"}). These findings combined with the small-molecule and lipophilic nature of the SIK inhibitors led us to further investigate the use of SIK inhibitors for topical eumelanization of human skin.

Second-Generation SIK Inhibitors Are as Efficacious in Inducing the Pigmentation Pathway as HG 9-91-01 {#S5}
------------------------------------------------------------------------------------------------------

Since there are limitations to topical delivery of HG 9-91-01 into human skin epidermis ([Figures 4A--4D](#F4){ref-type="fig"}), we derived SIK inhibitors designed to enhance passive epidermal permeation utilizing Lipinski's Rule of Five, which predicts greater absorption of compounds if they have fewer than five H-bond donors, fewer than ten H-bond acceptors, a molecular weight less than 500 g/mol, and calculated log P (CLogP) less than 5 ([@R4]; [@R5]; [@R21]) ([Figure S3A](#SD1){ref-type="supplementary-material"}). In an initial screen, two second-generation SIK inhibitors, YKL 06-061 and YKL 06-062, induced darkening as measured by reflective colorimetry analysis after topical treatment of human breast skin explants ([Figure S3B](#SD1){ref-type="supplementary-material"}). Furthermore, both YKL 06-061 and YKL 06-062 have a lower molecular weight than HG 9-91-01, and the more efficacious YKL 06-061 has a lipophilicity closer to Lipinski's Rule of Five, possibly explaining the drug's enhanced penetration capabilities ([Figure S3A](#SD1){ref-type="supplementary-material"}). Second-generation inhibitors had half maximal inhibitory concentration (IC~50~) values for the inhibition of SIK1, SIK2, and SIK3 that were comparable to those of HG 9-91-01 ([Figure 3A](#F3){ref-type="fig"}). To assess the kinome selectivity information of new analogs, YKL-06-061 was screened across a panel of 468 human kinases at a concentration of 1 µM using the KinomeScan methodology (DiscoverX). YKL-06-061 exhibited an S(1) score of 0.02, with 16 kinases displaying tight binding to it (Ambit scores of ≤1) ([Figure 3B](#F3){ref-type="fig"}). As the KinomeScan assays measure binding, we also performed enzymatic assays for these targets either in house or using the SelectScreen Kinase Profiling Service at Thermo Fisher Scientific ([Figure 3C](#F3){ref-type="fig"}). YKL-06-061 inhibited only one kinase, fyn-related kinase (FRK), more strongly than SIKs, which demonstrates its high overall selectivity ([Figure 3C](#F3){ref-type="fig"}). We anticipate that YKL-06-062 has similar kinase selectivity, considering their high structural similarity. Similar to observations with HG 9-91-01, treatment of normal human melanocytes ([Figures S3C and S3D](#SD1){ref-type="supplementary-material"}), UACC62 human melanoma cells, and UACC257 human melanoma cells ([Figures S1B, S1C, S1E, and S1F](#SD1){ref-type="supplementary-material"}) with YKL 06-061 or YKL 06-062 for 3 hr yielded a dose-dependent increase in MITF mRNA expression. Levels of *TRPM1* mRNA increased after MITF induction upon treatment with YKL 06-061 or YKL 06-062 in normal human melanocytes and UACC257 human melanoma cells ([Figures S1G, S1H, S3E, and S3F](#SD1){ref-type="supplementary-material"}).

Topical SIK Inhibitors Induce Human Skin Eumelanization {#S6}
-------------------------------------------------------

Treatment of human skin explants with passive topical application of the second-generation SIK inhibitors, YKL 06-061 and YKL 06-062, induced significant pigmentation after 8 days of treatment (1×/day), but no significant gross pigmentation was observed in skin treated with HG 9-91-01 ([Figure 4A](#F4){ref-type="fig"}). Fontana-Masson staining revealed increased melanin content in skin treated with YKL 06-061 or YKL 06-062 and marginally increased melanin in skin treated with HG 9-91-01, as compared with control ([Figure 4B](#F4){ref-type="fig"}). This effect was reproducible with independent preparations of synthesized drugs applied passively (via pipette) to the top of different human skin explants ([Figure 4C and 4D](#F4){ref-type="fig"}). Mechanical application of the first-generation SIK inhibitor HG 9-91-01, by rubbing via an applicator, induced significant gross pigmentation ([Figure 4E](#F4){ref-type="fig"}), and increased melanin content was observed upon Fontana-Masson staining of skin sections ([Figure 4F](#F4){ref-type="fig"}), suggesting that HG 9-91-01's limited human skin penetration can be, at least partially, overcome through mechanical application. YKL 06-061 and YKL 06-062 did not require mechanical application (rubbing) to induce significant human epidermal darkening.

DISCUSSION {#S7}
==========

These results illustrate the development and successful application of small-molecule SIK inhibitors for topical induction of skin pigmentation independently of UV irradiation in human skin. SIK inhibitors were shown to induce enhanced expression of the MITF transcription factor, which is known to regulate expression of numerous pigment enzymes that promote biosynthesis of eumelanin. A new generation of SIK inhibitors was developed, based on strategies for enhancing the likelihood of skin penetration through optimizing molecular size and lipophilicity. Two such SIK-targeted inhibitors, YKL 06-061 and YKL 06-062, were shown to induce similar responses both in vitro and when applied to human skin explants. In addition to upregulating mRNA levels of *MITF* and *TRPM1*, topical SIK inhibitors were seen to trigger the transfer of melanosomes into epidermal keratinocytes in a manner that recapitulates the perinuclear capping (subcellular localization) seen in normal human epidermal pigmentation. Thus, SIK-inhibitor treatments appear to induce not only synthesis of melanin but also melanosomal maturation, export, and localization features, even after import into keratinocytes. These features closely resemble the previously observed behavior of forskolin treatment in red-haired mice ([@R8]).

Topical application of small-molecule, UV-independent pigment inducers has not yet been examined in humans and would require careful considerations of safety. For example, the induction of dark pigmentation is associated with the lowest risk of most skin cancers in humans ([@R1]; [@R26]), and this pigment synthesis is believed to be dependent upon MITF ([@R2]). However, fixed genomic mutation or amplification of the *MITF* gene can be oncogenic in certain contexts ([@R3]; [@R11]; [@R36]). Reversible upregulation of MITF, as reported here, is also likely to occur in routine instances of UV tanning, and constitutive elevation of MITF is likely in the skin of individuals with darker pigmentation levels; neither would be anticipated to trigger genomic mutation of the *MITF* gene. Analogously, transient administration of recombinant hematopoietic growth factors has not been associated with formation of oncogenic transformation or leukemia ([@R9]; [@R24]). In mice, topical forskolin's pigmentary rescue in "redheads" resulted in significant protection from UV carcinogenesis, without apparent associated toxicities over many months of treatment ([@R8]). A recent study has utilized injections of the synthetic alpha-MSH analog, afamelanotide, for treatment of photosensitivity associated with erythropoietic protoporphyria. Pigmented lesions/melanoma were carefully evaluated and reported not to occur at elevated risk ([@R19]).

Our in vivo studies demonstrate that topical SIK inhibitor can be applied with localized SIK inhibition and no detected systemic effects in mice (such as failure to thrive); and although it has been previously shown that SIK1 inhibition leads to cell-cycle arrest in epithelial cells, this was dependent on the presence of transforming growth factor β (TGF-β) ([@R21]), and we observed normal skin turnover with no morphological changes of the skin (measured grossly or histologically, other than pigment/color). During normal UV-induced tanning, MC1R activation leads to enhanced PKA activity ([@R23]), and PKA-dependent phosphorylation of SIK1 ([@R30]), SIK2 ([@R12]), and SIK3 ([@R14]) decreases their kinase activity. Since our compounds' activity is analogous to the on/off switch of UV-induced tanning, we believe that it will be a safe, viable method of topical pigment production, though it may be important to assure localized delivery to skin.

The half-life of melanin in skin is thought to be several weeks and diminishes primarily after superficial keratinocyte sloughing. Most epidermal melanin resides within keratinocytes after transfer of melanosomes from melanocytes. Therefore, it is possible that small-molecule approaches like that described here might be achievable, or maintained, through intermittent pulse-dosing strategies, thereby further limiting systemic drug exposure. In conclusion, these studies describe a small-molecule, topical approach to the rescue of eumelanin synthesis in a UV-independent manner. Future studies will be needed to examine the optimal applications of such agents in a variety of clinical settings.

EXPERIMENTAL PROCEDURES {#S8}
=======================

See the [Supplemental Information](#SD1){ref-type="supplementary-material"} for detailed methods.

Materials {#S9}
---------

SIK inhibitors were dissolved in 30% propylene glycol plus 70% ethanol. HG 9-91-01 was purchased from Medchem Express, and all other SIK inhibitors were synthesized by the authors.

Kinome Profiling {#S10}
----------------

Kinome profiling was performed using KinomeScan ScanMAX at a compound concentration of 1 µM. Data are reported in the [Supplemental Information](#SD1){ref-type="supplementary-material"}. Protocols are available from DiscoverX.

Kinase Activity In Vitro Assay {#S11}
------------------------------

The biochemical activities against SIK2 were measured with a Caliper-based mobility shift assay (PerkinElmer).

Real-Time qPCR {#S12}
--------------

The relative expression of each gene was calculated with 7500 Fast Real-Time PCR System software, which utilizes *Ct* normalized to mRNA levels of *RPL11* to calculate relative expression. Results are reported relative to control cells.

Mice {#S13}
----

C57BL/6J *Mc1r^e/e^* mice were crossed with K14-SCF transgenic mice, and C57BL/6J *Tyr*^c2j/c2j^ were crossed with K14-SCF transgenic mice ([@R8]; [@R18]). Mixed-gender adult mice were used. All animal experiments were performed in accordance with institutional policies and Institutional Animal Care and Use Committee-approved protocols.

Human Tissue Samples {#S14}
--------------------

Skin samples considered surgical waste were obtained de-identified from healthy donors undergoing reconstructive surgery, according to institutional regulation.

Colorimeter Measurements {#S15}
------------------------

Differences in darkening of the skin were measured by reflective colorimetry (Commission Internationale de l'Eclairage \[CIE\] L\* white-black color axis) utilizing a CR-400 Colorimeter (Minolta) calibrated to a white standard background calibration plate, with calibration date set to Y 93.1, x 0.3133, y 0.3194, before each set of measurements.

Statistical Analysis {#S16}
--------------------

Data are presented as the mean ± SEM.

Statistical significance of differences between experimental groups for in vitro experiments of cell lines treated with varying doses of SIKi or vehicle control were assessed by one-way ANOVA with Dunnett's multiple comparisons post-test. In vitro time course experiments were assessed by repeated-measures one-way ANOVA with Dunnett's multiple comparisons post-test.

Statistical significance for colorimeter readings in [Figure 2B](#F2){ref-type="fig"} was determined by multiple t test analysis between day 0 and day 7 for each treatment group, with the two-stage linear step-up procedure of Benjamini, Krieger, and Yekutieli to correct for false discovery rate (FDR)---desired FDR (Q) = 1%---with no assumption of consistent SD. Statistical significance for colorimeter readings in [Figure S3B](#SD1){ref-type="supplementary-material"} were assessed by one-way ANOVA with Dunnett's multiple comparisons post-test.

For the G361 melanoma cells transduced with LKB1, a one-way ANOVA was used, with Dunnett's multiple comparisons test to assess the statistical significance of LKB1 expression and a two-tailed paired t test to assess the statistical significance of MITF induction with SIK-inhibitor treatment.

Statistical significance of differences between experimental groups for in vivo time course experiments was assessed by two-way ANOVAs with Sidak's multiple comparisons test.

Multiplicity-adjusted p values were reported for each comparison, and differences of means were considered significant if p \< 0.05.

Supplementary Material {#SM}
======================

[SUPPLEMENTAL INFORMATION](#SD1){ref-type="supplementary-material"}

[Supplemental Information](#SD1){ref-type="supplementary-material"} includes Supplemental Experimental Procedures, three figures, and one data file and can be found with this article online at <http://dx.doi.org/10.1016/j.celrep.2017.05.042>.
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![Inhibition of SIK by HG 9-91-01 Promotes *MITF* Transcription and Pigmentation In Vitro\
(A) mRNA expression of *MITF* relative to *RPL11* mRNA and vehicle control in normal human melanocytes 3 hr after HG 9-91-01 or vehicle control (70% ethanol, 30% propylene glycol) treatment, quantified by qRT-PCR (n = 3, mean ± SEM).\
(B and C) mRNA expression of *MITF* (B) and *MITF*-dependent gene *TRPM1* (C) relative to *RPL11* mRNA and vehicle control at each time point, in normal human melanocytes over 24 hr after 4 µM HG 9-91-01 or vehicle control treatment, quantified by qRT-PCR (n = 3, mean ± SEM).\
(D) Cell pellets of UACC257 melanoma cells after 3 days of treatment with vehicle control or 4 µM SIK inhibitor HG 9-91-01 (image is representative of n = 3 experiments).\
For the graph in (A), statistical significance is reported as follows: \*\*\*p \< 0.001; \*\*\*\*p \< 0.0001, one-way ANOVA with Dunnett's multiple comparisons test comparing treatment dose to vehicle control. For the graphs in (B) and (C), statistical significance is reported as follows: \*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001; \*\*\*\*p \< 0.0001, repeated-measures one-way ANOVA with Dunnett's multiple comparisons test comparing each time point to time point 0.](nihms882886f1){#F1}

![Topical Treatment with HG9-91-01 Causes Robust Darkening that Is Progressive and Reversible in *Mc1r*^e/e^;K14-SCF Mice\
(A--D) Shown here: (A) *Mc1r*^e/e^;K14-SCF mice and *Tyr*^c/c^;K14-SCF mice before treatment (day 0) and after 7 days of treatment (day 7) with 30 µL vehicle control (70% ethanol, 30% propylene glycol) or 37.5 mM HG 9-91-01 (image is representative of n = 4 experiments). (B) Reflective colorimetry measurements (L\* white-black color axis; n = 4, mean ± SEM) and (D) melanin extraction (image is representative of n = 4 experiments) of the *Mc1r*^e/e^;K14-SCF mice and *Tyr*^c/c^;K14-SCF mice described in (A). (C) Skin sections of *Mc1r*^e/e^;K14-SCF mice described in (A) stained with Fontana-Masson (eumelanin) (top two panels) or H&E (bottom two panels); (magnification, 400×). White arrows represent nuclear capping; scale bar represents 25 µm.\
(E) *Mc1r*^e/e^;K14-SCF mice and *Tyr*^c/c^;K14-SCF mice before treatment (day 0) and after 6 days of treatment with 30 µL vehicle control (70% ethanol, 30% propylene glycol) or 37.5 mM HG 9-91-01 (day 6), and 40 days post-treatment (day 46) (vehicle mouse in day-46 photo is different from that in the day-0 and day-6 photos).\
(F and G) Reflective colorimetry measurements (CIE L\* white-black color axis) of (F) *Mc1r*^e/e^;K14-SCF mice and (G) *Tyr*^c/c^;K14-SCF mice treated as described in (E). Vehicle-treated *Mc1r*^e/e^;K14-SCF mice: n = 5 (days 0--19), and n = 4 (days 24--34); HG 9-91-01-treated *Mc1r*^e/e^;K14-SCF mice: n = 3; vehicle-treated *Tyr*^c/c^;K14-SCF mice: n = 3 (days 0--10), and n = 2 (days 11--20); HG 9-91-01-treated *Tyr^c/c^*;K14-SCF mice: n = 3 (mean ± SEM). For the graph in (B), statistical significance is reported as follows: \*\*\*\*p \< 0.0001, multiple t test analysis with the two-stage linear step-up procedure of Benjamini, Krieger, and Yekutieli. For the graphs in (F) and (G), statistical significance is reported as follows: \*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001; \*\*\*\*p \< 0.0001, two-way ANOVA with Sidak's multiple comparisons test comparing treatment to vehicle control at each time point.](nihms882886f2){#F2}

![Characterization of SIK Inhibitors\
(A) Structures of HG-9-91-01, YKL-06-061, and YKL-06-062 and their biochemical IC~50~s against SIKs.\
(B) KinomeScan kinase selectivity profile for YKL-06-061. YKL-06-061 was profiled at a concentration of 1 µM against a diverse panel of 468 kinases by DiscoverX. Kinases that exhibited a score of 1 or below are marked in red circles. (Score is percent relative to DMSO control. Smaller numbers indicate stronger binding.) See [Table S1](#SD2){ref-type="supplementary-material"} for full kinome profile.\
(C) Biochemical kinase IC~50~s of YKL-06-061 top hits as shown in (B).\
TK, tyrosine kinase; TKL, tyrosine kinase-like; STE, homologs of yeast sterile 7, sterile 11, sterile 20 kinases; CK1, casein kinase 1; AGC, containing PKA, PKG, and PKC families; CAMK, calcium/ calmodulin-dependent protein kinase; CMGC, containing CDK, MAPK, GSK3, and CLK families. See also [Table S1](#SD2){ref-type="supplementary-material"}.](nihms882886f3){#F3}

![Treatment of Human Skin Explants with 37.5 mM of SIK Inhibitor Induces Pigmentation\
(A) Human breast skin explants treated with passive application of vehicle control (70% ethanol, 30% propylene glycol) or 37.5 mM SIK inhibitor YKL 06-061, YKL 06-062, or HG 9-91-01 for 8 days (10 µL; 1×/day). Image was taken 2 days after the end of treatment (image is representative of two of n = 3 experiments).\
(B) Fontana-Masson (top panel) and H&E (bottom panel) staining (magnification, 400×) of breast skin described in (A). Scale bar represents 25 µm.\
(C) Human breast skin explants treated with passive application of vehicle control or 37.5 mM SIK inhibitor YKL 06-061, YKL 06-062, or HG 9-91-01 for 5 days (10 µL; 2×/day). Image was taken 1 day after the end of treatment (image is representative of n = 1 experiment).\
(D) Human breast skin explants treated with passive application of vehicle control or 37.5 mM SIK inhibitor YKL 06-061, YKL 06-062, or HG 9-91-01 for 6 days (10 µL; 2×/day). Image was taken 1 day after the end of treatment (image is representative of n = 1 experiment).\
(E) Human breast skin explants treated with mechanical application of vehicle control or 50 mM (50 µL for 1 day; 1×/day) or 25 mM (50 µL for 3 days; 3×/day) HG 9-91-01. Image was taken 4 days after the start of treatment (image is representative of n = 1 experiment).\
(F) Fontana-Masson (top panels) and H&E (bottom panels) staining (magnification, 400×) of human skin explants described in (E). Scale bar represents 25 µm.](nihms882886f4){#F4}

###### Highlights

-   SIK inhibitors induce MITF, the master regulator of pigment genes in vitro

-   Topical SIK inhibitor treatment of redhead mice rescues melanin production

-   Human skin-permeable SIK inhibitors induce melanin production in human skin explants
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